Mn Services Vermogensbeheer B.V. Buys 11,300 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Mn Services Vermogensbeheer B.V. grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.3% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 492,155 shares of the biopharmaceutical company’s stock after buying an additional 11,300 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Gilead Sciences were worth $45,460,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in GILD. AMF Tjanstepension AB grew its position in Gilead Sciences by 14.7% during the third quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company’s stock valued at $33,645,000 after acquiring an additional 51,390 shares during the last quarter. Swedbank AB grew its holdings in shares of Gilead Sciences by 10.2% during the 3rd quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock valued at $171,672,000 after purchasing an additional 189,622 shares during the last quarter. Pallas Capital Advisors LLC lifted its stake in Gilead Sciences by 35.9% in the third quarter. Pallas Capital Advisors LLC now owns 7,836 shares of the biopharmaceutical company’s stock worth $696,000 after purchasing an additional 2,069 shares during the last quarter. Fortitude Family Office LLC grew its stake in shares of Gilead Sciences by 225.1% during the third quarter. Fortitude Family Office LLC now owns 829 shares of the biopharmaceutical company’s stock valued at $70,000 after buying an additional 574 shares during the last quarter. Finally, Farmers & Merchants Investments Inc. grew its holdings in shares of Gilead Sciences by 2.3% in the third quarter. Farmers & Merchants Investments Inc. now owns 8,861 shares of the biopharmaceutical company’s stock worth $743,000 after purchasing an additional 200 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on GILD. Barclays raised their price objective on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research report on Thursday, November 7th. Morgan Stanley raised their target price on shares of Gilead Sciences from $113.00 to $123.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Oppenheimer raised their price objective on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Finally, Royal Bank of Canada lifted their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a report on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $102.08.

Gilead Sciences Stock Down 1.0 %

Shares of GILD opened at $110.46 on Thursday. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $112.11. The stock has a market cap of $137.66 billion, a price-to-earnings ratio of 298.54, a P/E/G ratio of 0.71 and a beta of 0.18. The company has a 50-day moving average price of $96.56 and a two-hundred day moving average price of $89.49. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.86%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio (DPR) is 854.05%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 248,645 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the transaction, the chief financial officer now owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 542,001 shares of company stock valued at $52,230,551 in the last ninety days. Insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.